Edogawa-ku, Japan

Yutaka Kitagawa

USPTO Granted Patents = 11 


Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Edogawa-ku, JP (2006 - 2013)
  • Kanagawa, JP (2012 - 2016)
  • Tokyo, JP (2009 - 2024)

Company Filing History:


Years Active: 2006-2024

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Yutaka Kitagawa: Innovator in Antibody-Drug Conjugates

Introduction

Yutaka Kitagawa is a prominent inventor based in Edogawa-ku, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibody-drug conjugates. With a total of 11 patents to his name, Kitagawa's work has had a substantial impact on medical science.

Latest Patents

Among his latest patents, Kitagawa has developed a method for producing antibody-drug conjugates. This includes the creation of crystals of a compound represented by a specific formula, along with methods for their production. Another notable patent involves the preparation method for an optically active bicyclic gamma-amino acid compound. This invention aims to provide a high-purity optically active bicyclic gamma-amino acid derivative, achieved through a mixture of compounds represented by general formulas.

Career Highlights

Throughout his career, Yutaka Kitagawa has worked with esteemed companies such as Daiichi Sankyo Company, Limited and Daiichi Pharmaceutical Co., Ltd. His expertise in pharmaceutical innovation has positioned him as a key figure in the industry.

Collaborations

Kitagawa has collaborated with notable coworkers, including Makoto Muto and Yuichiro Tani. Their combined efforts have contributed to advancements in the field of drug development.

Conclusion

Yutaka Kitagawa's innovative work in the pharmaceutical sector, particularly in antibody-drug conjugates, showcases his dedication to advancing medical science. His numerous patents reflect his commitment to improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…